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Abstract
In addition to regulating the neuroendocrine stress response, corticotropin-releasing hormone (CRH)
has been implicated in both normal and pathological behavioral and cognitive responses to stress.
CRH-expressing cells and their target neurons possessing CRH receptors (CRF1 and CRF2) are
distributed throughout the limbic system, but little is known about the regulation of limbic CRH
receptor function and expression, including regulation by the peptide itself. Because CRH is released
from limbic neuronal terminals during stress, this regulation might play a crucial role in the
mechanisms by which stress contributes to human neuropsychiatric conditions such as depression
or posttraumatic stress disorder. Therefore, these studies tested the hypothesis that CRH binding to
CRF1 influenced the levels and mRNA expression of this receptor in stress-associated limbic regions
of immature rat. Binding capacities and mRNA levels of both CRF1 and CRF2 were determined at
several time points after central CRH administration. CRH downregulated CRF1 binding in frontal
cortex significantly by 4 h. This transient reduction (no longer evident at 8 h) was associated with
rapid increase of CRF1 mRNA expression, persisting for >8 h. Enhanced CRF1 expression—with a
different time course—occurred also in hippocampal CA3, but not in CA1 or amygdala, CRF2
binding and mRNA levels were not altered by CRH administration. To address the mechanisms by
which CRH regulated CRF1, the specific contributions of ligand-receptor interactions and of the
CRH-induced neuronal stimulation were examined. Neuronal excitation without occupation of
CRF1 induced by kainic acid, resulted in no change of CRF1 binding capacity, and in modest
induction of CRF1 mRNA expression. Furthermore, blocking the neuroexcitant effects of CRH (using
pentobarbital) abolished the alterations in CRF1 binding and expression. These results indicate that
CRF1 regulation involves both occupancy of this receptor by its ligand, as well as “downstream”
cellular activation and suggest that stress-induced perturbation of CRH–CRF1 signaling may
contribute to abnormal neuronal communication after some stressful situations.
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INTRODUCTION
The neuropeptide corticotropin-releasing hormone (CRH) functions as a key mediator of the
responses to stress (57). It has been increasingly recognized, however, that, in addition to its
neuroendocrine effects, CRH acts as a neuromodulator in stress-associated limbic regions to
propagate and integrate stress-induced behaviors. Specifically, at the cellular level, CRH has
been shown to enhance synaptic efficacy [e.g., LTP (35,38)]. In addition, abnormally high
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CRH levels at the synapse may lead to excessive excitability and contribute to some
developmental seizures (7). CRH functions via activation of specific membrane-spanning G-
protein coupled receptors, and both CRH-expressing cells and target neurons possessing these
specific receptors (CRF1 and CRF2) are abundant throughout the limbic system (3,16–18,22,
53).
Whereas information about the regulation of the expression of CRH itself, both in the
hypothalamus and in stress-related limbic regions, has been forthcoming (26,27,40,50), the
regulation of CRF1 expression in these regions has remained relatively unexplored. The
majority of studies investigating regulation of CRH receptors have centered on the
hypothalamic paraventricular nucleus (PVN), where, in response to stress, clusters of CRH-
producing cells release the peptide into hypothalamic-pituitary portal vessels. In PVN, stress
has been shown to increase gene expression of CRF1 (33,41,48). Other studies have addressed
this issue in pituitary corticotrophs bearing CRH receptors, which are stimulated by CRH to
secrete ACTH (1,28,59): CRF1 expression in pituitary corticotrophs was modulated by stress
in a biphasic manner—a reduction at 2 h was followed by an increase at 4 h (47)—raising the
possibility of altered receptor turnover. The only published investigation of the regulation of
brain CRH receptor mRNA after acute stress found changes in CRH receptor expression that
were confined to the hypothalamus (48).
Thus, limited information is available on the regulation of CRH receptors in limbic structures
such as hippocampus, amygdala, and cortex. In essence, a single study has suggested that
chronic stress in adult rats resulted in a decrease in CRF1 mRNA in frontal cortex while
increasing CRF1 expression in hippocampus (34).
An important aspect of the regulation of CRH receptors involves the consequences of their
occupation and activation by the ligand, CRH. Indeed, modulation of receptor expression by
the cognate neurotransmitter has been well established. A number of studies have shown that
endogenous CRH is probably the ligand for CRH receptors in the limbic system: CRH release
by physiological stimuli (e.g., during stress) has been shown in amygdala (43,54), hippocampus
(7,27,50), and other regions containing CRF1. Therefore, the changes in CRF1 expression that
have been reported after stress may be mediated directly by stress-induced CRH release and
binding to these receptors, or alternatively, by other stress-related molecules, e.g.,
glucocorticoids.
To begin addressing these alternative regulatory mechanisms, the current experiments were
designed to (i) determine if CRH directly regulated limbic CRF1 and CRF2 mRNA levels using
in situ hybridization, (ii) determine if CRH directly regulated its receptors at the protein level
by analyzing receptor binding capacity in tissue homogenates, and (iii) dissect out the specific
factors (i.e., ligand–receptor interaction, stress, or CRH-induced activation of signal
transduction cascades) involved in the mechanisms of CRH effects on CRF1 and CRF2
expression and abundance.
EXPERIMENTAL PROCEDURES
Animals and Tissue Preparation
Immature rats were used in these studies for two reasons: (i) Previous work from the authors’
laboratories had characterized hippocampal, amygdala, and hypothalamic CRH expression
during this age (26,27,60). (ii) Limbic CRH and CRH receptor expression may be particularly
robust during the second and third postnatal week in the rat (3,17,22,46). Ten-day old rats of
both sexes used in this study were offspring of timed-pregnancy Sprague–Dawley-derived
dams (Zivic-Miller, Zelienople, PA). Animals were maintained in NIH-approved facilities on
a 12-h light/dark cycle with access to unlimited lab chow and water. Cages were monitored
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every 12 h for the presence of pups and the date of birth was considered day 0. Litters were
culled to 12 pups and mixed among experimental groups (n = 5–10 per group). Potential diurnal
variability was addressed by initiating all experiments between 0800 h and 1000 h, and cages
were undisturbed for 24 h prior to initiation of experiments. For obvious technical reasons,
experiments were performed in “batches.” However, each included both experimental animals
and littermate controls, and tissue processing and data analyses were performed to include all
experiments. All experimental procedures were approved by the Institutional Animal Care
Committee and conformed to National Institutes of Health guidelines.
Surgical Procedures and CRH Administration
For CRH infusion, pups were implanted with stainless steel cannulae into the left lateral
cerebral ventricle, using halothane anesthesia, on the day preceding the experiments, as
described in detail elsewhere (6,13). Stereotaxic coordinates using Bregma as landmark were:
AP −0.7, L 2.0, V 3.3. Peptide infusion or the infusion of an equal volume of vehicle, was
carried out on postnatal days 10–12 to freely moving pups, using a Kd-Scientific multi-
microinfusion pump (Boston, MA) via a Hamilton syringe attached to flexible tubing (6,13).
The dose of CRH (0.75 nmol in 1.3 μ,L) was selected based on previous dose–response studies
(6). The dose used here has been shown to lead to activation of limbic neuronal populations,
i.e., behavioral, as well as by electrographic seizures (Fig. 1). The convulsant effects of the
dose of CRH used here lasted ~3 h (see Ref. 11 for EEG procedures). The specificity of the
effects of this dose of CRH was evident from their prevention by preadministration of
nonselective antagonists of CRH that block both CRF1 and CRF2 receptors. In addition, the
activatory effects of this CRH dose in limbic regions have been blocked by nonpeptide,
selective antagonists of the CRF1 receptor subtype (6).
An additional group of animals received an anesthetic dose (40 mg/kg) of the short-acting
barbiturate, pentobarbital, via intraperitoneal (ip) injection 5 min prior to infusion of CRH or
vehicle. This dose was calibrated to block both the behavioral and the electrographic convulsant
action of CRH (Fig. 1). Another group of cannula-carrying animals received an ip injection of
the limbic excitant kainic acid (KA) at a dose of 1.2 mg/kg. This dose was chosen to
approximate the magnitude and duration of CRH-induced excitation (seizures) of immature
rat neurons [Fig. 1 (11)].
Animals were decapitated at 2, 3, 4, 6, or 8 h after drug infusion and brains were rapidly
dissected onto powdered dry ice and stored at −80°C. For in situ hybridization, sections were
cut coronally at 20 μm using a cryostat, mounted on gelatin-coated slides and stored at −80°
C. For homogenate-binding studies, frontal cortices were isolated and frozen on powdered dry
ice. Trunk blood was collected for measurement of plasma corticosterone levels using a
commercial radioimmunoassay (RIA) kit (ICN, Irvine, CA).
Radioligand Binding Studies
Membrane preparation—On the day of the assay, frontal cortex tissues were thawed on
ice, weighed and placed in 5 to 7-mL ice-cold PBS containing 10 mM MgCl2, 2 mM EGTA,
pH 7.0 (assay buffer), at 22°C and homogenized at maximum setting on a tissue tearer (Model
985–370; Biospec Products, Inc.) for 20 s on ice. Membrane homogenates were then washed
twice by centrifugation (30,000 g for 10 min at 4°C) in the same buffer (5–7 mL). These
extensive membrane washes virtually exclude the possibility of residual peptide after CRH
administration in vivo. The final pellets were resuspended in buffer to a working concentration
of approximately 25 mg/mL protein original wet weight. Final protein concentrations were
determined using the BCA protein determination assay from Pierce Biochemical Co.
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(Rockford, IL) and quantified using bovine serum albumin (BSA) as a standard. Typically the
final protein concentrations in the assay ranged from 200–300 μg/tube.
Tyr°-sauvagine binding studies—Radioligand binding of [125I]Tyr°-sauvagine ([125I]
sauvagine) in rat brain membranes was performed essentially as previously described (25).
Briefly, 1.5-mL Eppendorf tubes received, in order, 50 μL buffer, 50 μL competing drug, 50
μL of [125I]sauvagine, and 150 μL membrane suspension as described above for a total assay
volume of 300 μL. (All drugs and reagents were made up in assay buffer). The assay was
incubated at equilibrium routinely for 2 h at 22°C as determined by direct kinetic experiments
for the association of [125I] sauvagine binding (25). Nonspecific binding was defined in the
presence of 1 μM unlabeled peptide antagonist D-Phe12, Nle21,38, Ala32 human CRF-[12–41]
(D-Phe-CRF). Reactions were terminated by centrifugation in Beckman microfuge for 10 min
at 12,000 g. The resulting pellets were washed gently with 1 mL of ice-cold PBS containing
0.01% Triton X-100 and centrifuged again for 10 min at 12,000 g. The supernatants were
aspirated and the tubes cut just above the pellet and placed into 12 × 75-mm polystyrene tubes
and monitored for radioactivity in a Packard Cobra II γ-counter at approximately 80%
efficiency.
Quantification of CRF1 and CRF2 receptor concentration—The determination of
[125I]sauvagine binding to the CRF1 receptor was specifically defined in the presence of 3
μM NBI 27914, a compound that has been shown to have no binding activity to the CRF2
receptor subtype (15). In tissues such as the olfactory bulb, where both CRF1 and CRF2
receptors exist (14), 3 μM NBI 27914 completely blocked [125I] sauvagine binding to the
CRF1 receptor subtype, leaving a substantial amount of [125I] sauvagine bound. In the same
tissues, 1 μM D-Phe-CRF was able to completely block the binding to both receptor subtypes.
The difference between the binding in the presence of NBI 27914 and the binding in the
presence of D-Phe-CRF was thus defined as specific binding of [125I] sauvagine to the CRF2
receptor subtype. The concentration of [125I]sauvagine used in these studies was 600–800 pM,
achieving >85% fractional receptor occupancy of both receptor subtypes based on their KD
values (~ 150 pM). Values therefore are listed as receptor concentration approximating Bmax
levels. In this way, direct comparisons of the effects of treatment on the relative receptor levels
could be obtained.
In Situ Hybridization Histochemistry (ISH) Procedures for CRF1 and CRF2 Messenger RNAs
cRNA probe synthesis and preparation have been described previously (14,23). Briefly, a
plasmid containing a 600-bp fragment of CRF1 cDNA or 461-bp fragment of CRF2 cDNA was
linearized with HindIII. Radioactive antisense cRNA was synthesized using a T3 transcription
system in a standard labeling reaction mixture consisting of 1 μg linearized plasmid, 5×
transcription buffer, 250 μCi of [35S]CTP, 30 nmol NTPs, 50 nmol dithiothreitol, 40 U of
Rnasin, and 34 U of RNA polymerase. The reaction was incubated at 37°C for 1 h. The probes
were subjected to alkaline hydrolysis and purified by column chromatography [Select-D(RF),
5 Prime-3 Prime, Boulder, CO]. Probe specificities for both CRF1 and CRF2 mRNA have been
established (14).
ISH was performed as described previously for cRNA probes (23). Briefly, 20-μm coronal
sections were collected on gelatin-coated slides and stored at −80°C. Sections were thawed,
air-dried, fixed in paraformaldehyde, dehydrated and rehydrated through graded ethanols,
exposed to 0.25% acetic anhydride in 0.1 M triethanolamine (pH 8), and dehydrated.
Prehybridization (1 h) and hybridization steps were performed in a humidified chamber in a
solution of 50% formamide, 5× SET (0.75 M NaCl, 0.15 M Tris, 0.01 M EDTA), 0.2% SDS,
5× Denhardt’s, 0.5 mg/mL salmon sperm DNA, 0.25 mg/mL yeast tRNA, 100 mM
dithiothreitol, and 10% dextran sulfate. Following prehybridization, sections were hybridized
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overnight. For detection of CRF1 and CRF2 mRNA, sections were hybridized at 55°C with 1
× 106 cpm of 35S-labeled ribonucleotide probe complementary to CRF1 or CRF2 mRNA
(37). After hybridization, sections were digested with 200 μg/mL RNase A (Calbiochem, La
Jolla, CA) for 30 min at 37°C. Sections underwent serial washes of increasing stringency at
55°C, the most stringent at 0.03 × SSC for 1 h (23). Hybridized sections were apposed to film
(Hyperfilm βMax, Amersham, IL) for 7–14 days.
Semiquantitative Analysis of CRF1 and CRF2 mRNA and Statistical Considerations
Analysis of CRH mRNA ISH signal was performed on digitized films using the Image Tool
software program (University of Texas Health Science Center, San Antonio, TX) as described
elsewhere (23). Five anatomically matched sections per region per brain were analyzed,
without knowledge of treatment. Unbiased methods for section sampling have been described
in detail elsewhere (23). Cingulate cortex was sampled at the coronal level 2.9–3.2 mm anterior
to Bregma in the 10-day-old rat (49); frontal cortex was sampled at 2.9–3.2 mm anterior and
4–5 mm lateral with reference to bregma. Densities were calibrated using 14C standards and
are expressed in nCi/g after correcting for background by subtracting the density of the
hybridization signal over the corpus callosum. Differences among groups were determined
using a one-way analysis of variance (ANOVA) or Student t test, as appropriate (Prism
GraphPad, San Diego, CA) and significance levels were set at P < 0.05. Further analysis used
Tukey’s multiple comparison post hoc tests to determine the source of the detected significance
in the ANOVAs.
RESULTS
CRH Administration Reduces CRF1 Binding in Frontal Cortex
CRF1-binding capacity in homogenates of frontal cortex was significantly reduced by 4 h after
administration of CRH (CRH, 22.3 ± 1.4; controls, 28.4 ± 2 fmol/mg protein; Fig. 2A), whereas
no significant changes were found in CRF2 binding (CRH; 5.7 ± 0.4; controls, 5.3 ± 0.6 fmol/
mg protein; Fig. 2B). The effect on CRF1 binding in frontal cortex was transient and no longer
evident at 8 h after CRH administration (CRH, 28.9 ± 1.2; controls, 30.8 ± 1.5 fmol/mg protein;
t test, P = 0.36).
CRF1 mRNA Expression Is Enhanced in Select Regions of Frontal Cortex Following
Activation of the Receptor by CRH
CRF1 mRNA expression was robust in neocortical and hippocampal regions of the developing
rat brain (Fig. 3A). As a result of CRH administration, CRF1 mRNA levels were significantly
upregulated in specific neocortical regions. Figures 4A and 4B show enhanced levels in
cingulate cortex from CRH-infused animals (120 ± 7 nCi/g) as compared to vehicle-treated
controls (50 ± 4 nCi/g) at the 4-h time point. Interestingly, the onset of upregulation of CRF1
mRNA levels was evident by 2 h and this CRH-induced increase persisted for at least 8 h
posttreatment (36 ± 7.1% over controls, Fig. 4C).
A significant, rapid (by 2 h) upregulation (150 ± 25.2%) of CRF1 mRNA expression occurred
also in layers II/III of frontal cortex (Figs. 4A and 4B). This enhancement was short-lived and
returned to control values by 4 h after CRH administration, but a second wave of significant
elevation in CRF1 mRNA levels in these neuronal populations was observed at the 8 h time
point (44 ± 7.5%; Fig. 4C). In contrast to the superficial layers, no significant difference in
receptor expression between experimental and control groups was observed in layers V/VI of
neocortex, where CRF1 mRNA expression levels were much lower (Figs. 3A, 4A, and 4B).
In addition to frontal neocortex, CRF1 mRNA levels were analyzed in the CA1 and CA3
pyramidal layers of hippocampus proper and in the granule cell layer of dentate gyrus (Fig.
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4B) at 2, 4, 6, and 8 h after CRH administration. In hippocampus, significant upregulation of
CRF1 mRNA expression was observed in the CA3 pyramidal cell layer, peaking at the 4-h
time point (Fig. 5A). Time-course experiments demonstrated that the onset of CRH-induced
enhancement of CRF1 mRNA expression in the hippocampal CA3 region began later than in
neocortical regions, peaked at 4 h and returned to basal levels by 8 h following CRH
administration (not shown). No significant changes in CRH receptor expression were observed
for other analyzed hippocampal regions at any time point. In the amygdaloid complex, robust
CRF1 expression was noted in the basolateral nucleus (BLA, Figs. 3A and 4B), but this
expression was not altered by CRH administration at any time point analyzed (Fig. 5B).
CRF2 mRNA Expression Is Not Modulated by CRH Administration
CRF2 mRNA was confined primarily to subcortical regions of the immature rat brain (Fig.
3B), consistent with previous reports (14,22,23). No changes were observed in CRF2 mRNA
expression in hypothalamic and amygdalar regions with significant mRNA expression of this
receptor (22,23). Although only the 4-h time point is shown in Fig. 6, CRH administration did
not result in significant alteration of CRF2 mRNA levels in the ventromedial hypothalamic
nucleus or in the medial and basomedial amygdala nuclei at any of the analyzed time points.
Changes in CRF1 Expression and Binding Require Occupancy and Activation of This
Receptor by Its Ligand (CRH)
Central administration of CRH to immature rats results in several effects. These include: (i)
occupancy of CRH receptors, leading to activation of molecular signaling cascades in several
neuronal populations (21,31); (ii) behavioral and electrographic evidence of intense neuronal
stimulation [i.e., seizures (4)]; (iii) potentially, activation of the neuroendocrine responses to
stress, including elevation of plasma glucocorticoid levels, although the doses administered
have previously been shown not to enhance plasma glucocorticoids by themselves (4). To
determine which of these factors contributed to the mechanisms by which CRH modulated
CRF1 expression and binding capacity, several experiments were carried out.
The first experiment demonstrated that CRH binding to the receptor, by itself, was not sufficient
to modulate binding capacity (Fig. 7) or CRF1 mRNA expression (Fig. 8): to prevent molecular
and electrophysiological measures of neuronal activation, a group of animals were given the
short-acting barbiturate, pentobarbital, prior to CRH administration (11,56). As shown in Fig.
7, CRH-induced changes in CRF1 binding capacity in frontal cortex were eliminated by
pentobarbital administration, as was the enhancement of CRF1 mRNA levels in frontal cortex
layers II/III and hippocampal CA3 pyramidal cell layer (Figs. 8A and 8B).
Second, to determine whether the intense activation of limbic neurons (also induced by CRH)
and the resultant induction of signal-transduction cascades (27) were sufficient to alter CRF1
expression without the requirement for occupancy of this CRH receptor, a similar pattern and
degree of limbic neuronal activation were generated by administration of the limbic stimulant,
kainic acid (5,11). The compound induced prolonged limbic seizures which were of similar
phenotype and duration to those induced by CRH (5,11). In addition, kainic-acid-induced
seizures provoked glucocorticoid secretion, resulting in plasma levels similar to those arising
from CRH-induced seizures (Fig. 9). As noted above, previous studies have shown that the
dose of CRH utilized here is not sufficient to stimulate the pituitary gland to evoke release of
glucocorticoids from the adrenals by itself. Once CRH-induced seizures commence,
glucocorticoid levels are increased, suggesting that it is endogenous peptide released due to
stress from the seizures that triggers steroid secretion (4). Despite the similarities between
kainic acid and CRH as limbic stimulatory agents, kainic acid resulted in no significant change
of CRF1 binding capacity (Fig. 7). Kainic acid administration did enhance1 CRF mRNA levels
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significantly in neocortical layers II/II1 (Fig. 8A) and moderately in the hippocampal CA3
pyramidal cell layer (Fig. 8B) as compared to controls.
DISCUSSION
The major findings of the present study were (i) CRH administration to immature rats decreased
CRF1 binding capacity in frontal cortex, (ii) CRF1 mRNA expression increased in frontal
cortex and select hippocampal regions following CRH administration, and (iii) both occupancy
of this receptor by its ligand (CRH), and activation of postreceptor, “downstream” signal-
transduction cascades were required for this modulation of CRF1 binding levels and mRNA
expression.
Two specific, high-affinity receptors mediate the actions of CRH. These have been
characterized and localized to discrete brain regions throughout the central nervous system
(CNS; 3, 14, 18, 22). The CRF1 receptor, constituting the focus of this study, is distributed
primarily in cortical areas, as well as in anterior pituitary, whereas CRF2 is mainly found in
subcortical regions, including lateral septum and hypothalamus, as well as in choroid plexus
and cerebral vasculature. Consistent with similar studies in the adult (42), this study yielded
no evidence for regulation of CRF2 binding capacity or expression by CRH in any of the
examined brain regions of the immature rat. Thus, these two members of the CRH receptor
family demonstrate differing regulatory mechanisms, consistent with their subserving distinct
and separate functions.
CRH administration in the present study downregulated CRF1 binding in the frontal cortex.
This is particularly interesting, because alteration of both CRH and its receptor has been
demonstrated in a number of human disorders (19). For example, increased CRF1 binding
capacity has been shown in humans with Alzheimer’s dementia, where cortical levels of CRH
are low (9,37), suggesting that the increased receptor binding may be a compensatory
mechanism attempting to increase CRH-mediated neuronal communication. Furthermore,
reduced CRH receptor binding capacity in frontal cortex has been reported in depressed suicide
victims (44 but see 32), in whom cerebrospinal fluid CRH levels are increased (44). These
reciprocal alterations of the levels of CRH and CRF1 are consistent with regulation of the
receptor by its ligand in the human CNS. The relationship between altered binding capacity
and mRNA levels of CRF1, however, has not been previously examined (see below).
Whereas decreased binding capacity of CRF1 was shown in homogenates derived from frontal
cortex and thus consisting of all cortical layers (I–VI), in situ hybridization permitted a higher
resolution, demonstrating specific effects of CRH administration on CRF1 mRNA expression
in superficial (II/III) but not in deeper cortical layers (V/VI). Based on previous studies by our
laboratory and others (10,21), it is unlikely that the differential effects on CRF1 mRNA
expression were due to the inability of centrally administered CRH to diffuse equally to all
populations of CRH receptors. High levels of CRF1 mRNA and protein have been reported in
all of these cortical layers (14,16). Our findings raise the possibility of potential specific roles
of CRF1 located in discrete neocortical layers.
CRH also enhanced CRF1 mRNA expression throughout the cingulate cortex (medial
prefrontal cortex). Enhanced levels of cingulate-CRF1 receptors could contribute to the
proposed role of this region in modulation of HPA axis function in response to stress (20).
Specifically, stress levels of CRH may interact with CRF1-bearing neurons in the cingulate
cortex to promote negative feedback onto the hypothalamic–pituitary adrenal axis via indirect
pathways from this region that project to hypothalamic CRH-expressing neurons (e.g., via
septum or nucleus of the solitary tract). This should result in reduction of CRH secretion from
these PVN neurons.
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It should be noted that no alteration of CRF1, mRNA levels by CRH was observed in the
amygdala. CRF1 has been considered a major mediator for many of the central
neuromodulatory effects of CRH (6,54). For example, mice deficient in CRF1 demonstrate
reduced anxiety and an impaired stress response (50,55), attributed to amygdala functions.
Thus, using selective antagonists, CRF1 receptors in the amygdala were shown to mediate
anxiogenesis (54). Within the amygdala complex, the central nucleus (ACe) has been suggested
to be the primary site of these central CRH effects, but although substantial CRF1-like
immunoreactivity is found in ACe (16), neurons in this nucleus express low levels of CRF1
mRNA (14). This may suggest that the origin of the immunoreactive CRF1 may lie outside the
ACe. In the context of the current findings, the lack of alteration of CRF1 mRNA levels in
basolateral amygdala by any of the stressful manipulations performed in this study, as well as
by the administration of CRH itself, indicates that in this region, CRF1 mRNA expression is
probably not significantly regulated by stress or by CRH binding.
Unlike in the amygdala, CRF1 mRNA levels in the hippocampal CA3 pyramidal layer, a region
where high levels of CRF1 mRNA (3,14) and of CRF1-like immunoreacvity (16) have been
demonstrated, were highly enhanced by CRH administration. This upregulation may have
important physiological consequences: in hippocampal slice preparations, CRH application
leads to excitatory discharges from CA1 and CA3 pyramidal neurons (2,30). In addition, high
doses of CRH infused icv to developing rats lead to hippocampal pyramidal cell injury (13)
and it is interesting to note that this injury occurs selectively in CA3 pyramidal cells (5,13).
While the mechanisms for this selective vulnerability of CA3 pyramidal neurons to CRH have
not been established, this subfield is particularly rich in CRF1 receptors (16), and as shown
here. CRH induces upregulation of CRF1 levels only in CA3 cells (not in CA1; Fig. 5A). The
potential importance of this effect of early life administration of CRH for hippocampal
pathophysiology during adulthood has recently been emerging: studies from this laboratory
(13) demonstrate that CRH binding to its receptor early in life may lead to prolonged
upregulation of CRF1 mRNA expression which persists up to 1 year. This receptor upregulation
is associated with progressive death of CA3 hippocampal neurons, suggesting that early life
modulation of CRH receptor expression and function may be a persistent and important factor
in neuronal dysfunction throughout life.
Thus, the findings of these experiments suggest that in CA3 pyramidal cells, CRH may induce
enhanced CRF1 expression long-term promoting exaggerated downstream effects of CRF1
activation, such as calcium entry (36,58), which may result in cellular injury (13) and contribute
to stress-related neurological disorders.
The current study demonstrated regulation of CRF1 levels and expression in cortical and limbic
regions of the immature rat. It should be noted that in previous studies performed in the
adult rat, administration of a dose of CRH 10 times larger than those employed here resulted
in upregulation of CRF1 mRNA solely in PVN (42). A possible explanation for these
differences may derive from the enhanced potency of CRH in the activation of limbic neurons
during development, compared with the adult (4,7,12,21,24). This activation is mediated
specifically by CRF1 (6). Therefore, the current findings are consistent with the notion that in
order to regulate CRF1 levels and expression, not only occupancy of the receptor is required,
but also activation of downstream signal-transduction cascades, measurable by immediate
early genes (12), and electrophysiological or metabolic markers of neuronal activation (21).
This notion is further supported by the fact that administration of CRH in the presence of
pentobarbital did not lead to alteration of CRF1 binding or mRNA levels (Figs. 7 and 8).
Pentobarbital eliminated the central behavioral and electrophysiological measures of
hippocampal neuronal activation by CRH (4,12,21), while not altering peripheral stress effects,
i.e., glucocorticoid secretion (most likely induced by the stress of the injection: Fig. 9). These
findings suggest that in addition to receptor occupancy by the ligand (CRH), downstream
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activation of target neurons is required for modulation of CRF1. Furthermore, the lack of
correlation with plasma glucocorticoid levels suggests that these mechanisms may be
independent of peripheral steroid actions.
However, neuronal activation per se, in the absence of receptor occupancy by the ligand, does
not fully reproduce the effect of CRH administration on CRF1 levels: Provocation of intense
activation of limbic neurons using the excitatory agent kainic acid led to no changes in cortical
CRF1 binding (Fig. 7) and to an intermediate level of enhancement of mRNA levels (between
CRH and vehicle; Fig. 8). While neuronal activation is clearly required for this regulation (since
CRH-induced changes in CRF1 expression were suppressed by blocking neuronal activation
using pentobarbital) the data suggest that CRH itself also contributes to this regulatory effect.
In this context it may be noted that previous work from several laboratories has shown that
kainic acid and other agents promoting neuronal activation increase levels of CRH in
hippocampus and related limbic regions (27,45,50). Therefore, it is likely that, in the current
study, kainic acid administration increased CRF1 receptor levels in part via enhancement of
CRH levels in hippocampus and frontal cortex. Thus, this effect of kainic acid supports the
notion that the mechanism by which CRH regulates levels of CRF1 requires both the ligand,
CRH, and activation of postsynaptic signal transduction pathways.
The precise molecular events leading from receptor binding to modulation of receptor levels
and expression are not fully understood. The present study demonstrated a decline in CRF1
binding capacity in neocortex, associated with increased CRF1 mRNA expression. These
findings are consistent with a mechanism of transient receptor elimination due to
internalization, which leads to enhanced receptor mRNA transcription as has been shown in
several other G-protein-coupled receptor systems (8,29,52). In other systems, this ligand-
induced receptor internalization has been proposed to contribute to receptor desensitization via
cell surface receptor downregulation (8,29), as well as by regulating transcription of mRNA
(52).
The specificity of the changes in binding capacity and synthesis to CRF1 should be noted. The
fact that none of the manipulations in our studies led to changes in the CRF2 receptor reinforces
the notion that this receptor must be regulated in a different manner by its cognate ligand.
Because it has been shown that CRH has low affinity for this receptor subtype, the effects of
urocortin, a native endogenous neuropeptide with high affinity for CRF2, on expression and
binding capacity of this receptor will require evaluation.
In conclusion, the current studies strongly support both the presence as well as the clinical
importance of the complex regulatory effects of CRH on CRF 1 expression in cortical and
limbic regions. Because such reciprocal alterations in CRH-peptide and CRF1-receptor levels
have been observed in a number of human neuropathological states, understanding the
mechanisms by which CRH modulates its receptors is highly relevant to human
neuropsychiatric conditions.
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FIG. 1.
Effect of pentobarbital on electrophysiological activity induced by CRH in the dorsal
hippocampus. The tracings depict bipolar EEG recordings from 10-day-old rats. Baseline
recordings were taken 5 min prior to CRH administration. EEG recordings were obtained 30–
40 min following CRH or KA administration, and were correlated with limbic seizures
consisting of oral automatisms and forepaw clonus. Intraperitoneal injection of pentobabital
(P) abolished all CRH-induced electrophysiological activity in dorsal hippocampus within 5
min of drug administration. Arrowheads indicate spike-wave discharges and the arrow
indicates motion artifact. Horizontal bar, 1 s; vertical bar, 50 μV.
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FIG. 2.
CRH administration reduces CRF1 binding in frontal cortex of immature rats (5–6/group). (A)
CRF1 binding capacity in homogenates of frontal cortex was selectively downregulated, 4 h
after CRH administration (*P = 0.02, t test). (B) In contrast, no significant changes were found
in CRF2 binding capacity (P = 0.58, t test). Values are means ± SEM. (Note: the CRF1 binding
values also contribute to Fig. 7.)
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FIG. 3.
(A) CRF1 and (B) CRF2 mRNA expression patterns in immature (10-day-old) rat forebrain.
Representative computer-generated pseudo-color images of coronal hemisections following
in situ hybridization for CRF1 or CRF2 mRNA (red, high; yellow-green, medium; dark blue,
low mRNA levels) are shown. Cing, cingulate; Cx, cortex; HIPP, hippocampus; BLA,
basolateral amygdala; MEA, medial amygdala; BMA, basomedial amygdala; VMH,
ventromedial hypothalamus.
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FIG. 4.
CRF1 mRNA expression is selectively upregulated in cortical regions following CRH
administration. Semiquantitative analysis was performed after in situ hybridization for CRF1
on coronal sections from immature animals given CRH or vehicle (n = 5–10/group/time point
for A and C). The graph in (A) represents maximal CRH-induced increases of CRF1 mRNA
levels in cingulate cortex and cortical layer II/III (peak at 4 and 2 h, respectively). No significant
changes in CRF1 mRNA expression were detected in the deeper cortical layers V/VI at any
time point analyzed (4 h shown in graph). (B) Representative coronal sections from animals
administered CRH or vehicle, showing CRF1 mRNA expression. (C) The inverse temporal
relationship between binding capacity (protein levels) and mRNA levels of CRF1 receptors
after CRH administration; values given as percentage difference from those of vehicle-treated
rats. Values are means ± SEM. (Note: values for frontal cortex layer II/III are also incorporated
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in Fig. 8) *Significant difference from vehicle treated (P < 0.05, one-way ANOVA with
Tukey’s multiple comparison analysis). HIPP, hippocampus; BLA, basolateral amygdala;
Cing, cingulate; Cx, cortex.
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FIG. 5.
CRF1 mRNA expression is selectively upregulated in select hippocampal regions (A), but not
in amygdala (B) after CRH administration. Semiquantitative analysis of CRF1 mRNA signal
in coronal sections of immature rats (5–10/group) 4 h after infusion with CRH or vehicle. DG,
dentate gyrus. Values are means ± SEM. (Note: values for CA3 are also incorporated in Fig.
8) *Significant difference from vehicle treated (P < 0.05, one-way ANOVA with Tukey’s
multiple comparison analysis).
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FIG. 6.
CRH administration does not result in significant alterations of CRF2 mRNA levels in
hypothalamic or amygdala regions with high expression levels of this receptor.
Semiquantitative analysis of CRF2 mRNA signal in coronal sections of immature rats (5–10/
group) 4 h postinfusion with CRH or vehicle. VMH, ventromedial hypothalamus; MEA, medial
amygdala; BMA, basomedial amygdala. Values are means ± SEM.
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FIG. 7.
Regulation of CRF1 binding capacity by CRH requires both neuronal activation and receptor
occupancy by the ligand. CRH-induced changes in CRF1 binding capacity in homogenates of
frontal cortex are blocked in immature rats given pentobarbital (P) prior to CRH to prevent
neuronal activation. In addition, administration of the limbic convulsant kainic acid (KA) to
immature rats does not significantly alter CRF1 binding capacity in homogenates from frontal
cortex. *Significant difference from vehicle (n = 5 pups/group; P < 0.05, one-way ANOVA
with Tukey’s multiple comparison analysis). Values are means ± SEM. (Note: vehicle and
CRH values are also shown in Fig. 2.)
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FIG. 8.
Modulation of CRF1 mRNA levels in frontal cortex (A) and hippocampus (B) requires neuronal
activation. (A) Administration of CRH or kainic acid (KA) induced significant upregulation
of CRF1 mRNA expression in cortical layer II/III. (B) CRH, but not KA, enhances CRF1
mRNA expression in hippocampal CA3. In both frontal cortex and hippocampus, blocking the
excitatory effects of CRH with preadministration of pentobarbital (P) abolished the effects of
CRH on CRF1 mRNA levels. *Significant difference from vehicle and “significant difference
from vehicle and CRH + P (n = 5/group; P < 0.05, one-way ANOVA with Tukey’s multiple
comparison analysis). Values are means ± SEM. (Note: values for vehicle and CRH in (A) and
(B) are also shown in Figs. 4 and 5, respectively.)
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FIG. 9.
Plasma corticosterone (cort) levels are significantly elevated 30 min after treatment with kainic
acid (KA), CRH, or pentobarbital (P) together with CRH (CRH + P). Both CRH- and KA-
treated animals demonstrated overt behavioral neuronal activation (seizures) at the time of
sacrifice, whereas pentobarbital blocked this activation in CRH + P-treated animals. Thus,
peripheral corticosterone levels did not correlate with limbic neuronal activation. *Significant
difference from vehicle and stress-free controls (SF; unmanipulated and sacrificed within 20
s of disturbance; n = 5–10/group; P < 0.05, one-way ANOVA with Tukey’s multiple
comparison analysis). Values are means ± SEM.
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